Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The study design is a double-blind, randomized, active-control trial of adolescents (ages
13-18 years) with recent suicidal behaviors (suicide attempt or increased suicidal ideation).
All participants will be treated through a suicide prevention IOP (typically 6-8 weeks), as
well as clinically indicated psychosocial and/or psychopharmacological treatments.
Ketamine/midazolam treatment will occur twice weekly during the first two weeks of the study,
followed by weekly assessments through week 12.